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Abstract 
Background 
Poor sleep quality is common in haemodialysis patients and associated with worse outcomes. In this 
pre-specified analysis, we examined the impact of extended hours haemodialysis on sleep quality. 
Methods 
The ACTIVE Dialysis trial randomized 200 participants to extended (≥24 hours/week) or standard 
(target 12-15 hours) hours haemodialysis over 12 months. Sleep quality was measured in the 
Kidney Disease Quality of Life Short Form 1.3 (KDQOL-SF) by overall sleep quality score (0-10, 
10 = “very good”) and the sleep subscale (0-100, 100 = ‘best possible sleep’) every three months 
via blinded telephone interviewer. The average intervention effect was calculated by mixed linear 
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regression adjusted by time point and baseline score.  Factors predicting sleep quality were assessed 
by multivariate regression analysis. 
Results 
Overall sleep quality score and sleep subscale at baseline were similar in both groups (5.9 [95%CI 
5.4-6.4] vs 6.3 [5.9-6.8]; 65.0 [60.9-69.1] vs 63.2 [59.1-67.3]; extended and standard hours 
respectively).  Extended hours haemodialysis led to a non-significant improvement in overall sleep 
quality score (average intervention effect 0.44 (-0.01-0.89), p=0.053) and sleep subscale (average 
intervention effect 3.58 (-0.02-7.18), p= 0.051). Poor sleep quality was associated with being 
female and with current smoking.  Sleep quality was positively associated with EuroQol-5D 
(EQ5D) and the SF-36 Physical Component and Mental Component Summary Scores but not with 
hospitalisations. 
 
 
 
Conclusions 
Sleep quality was not significantly improved by extended hours dialysis in this study. Sleep quality 
is positively correlated with quality of life in haemodialysis patients and is poorer in women and 
current smokers.  
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Introduction 
 
Poor sleep quality and daytime sleepiness are reported to affect 20-83% of patients with end-stage 
renal disease (ESRD) treated with dialysis1, 2. There are multiple postulated causes for this, 
including sleep apnoea, restless legs syndrome (RLS) and symptoms of kidney disease2-4. Previous 
studies have highlighted that poor sleep is associated with increased mortality and poor quality of 
life2, 5, 6. Patients place high importance on sleep, with the prospect of better sleep substantially 
more likely to induce them to extend their dialysis hours than the prospect of lengthened life 
expectancy7. 
The impact of extended hours haemodialysis on sleep quality is uncertain. Short daily 
haemodialysis six times per week has been associated with reduced symptoms of RLS and sleep 
improvements8 while extended nocturnal haemodialysis 6-7 nights per week has been associated 
with improvements in obstructive sleep apnoea4. However, two previous randomised-controlled 
trials did not show an improvement in subjective sleep quality with frequent dialysis (5-6 times per 
week) compared to standard thrice weekly dialysis9, 10. 
The ACTIVE Dialysis trial randomised 200 participants to extended or standard hours 
haemodialysis for 12 months resulting in a doubling of weekly haemodialysis hours (median 
weekly hours 24.0 (inter-quartile range (IQR) 23.6, 24.0) versus 12.0 (IQR 12.0, 16.0) in the 
extended and standard groups respectively. The intervention had no effect on the primary outcome 
of quality of life at 12 months as measured by EuroQol-5D-3L (EQ5D) (mean difference 0.037, 
95% CI 0.032, 0.105, p=0.29). However, there was a small, statistically significant improvement in 
Physical Component Summary (PCS) and Mental Component Summary (MCS) of 2.30 (95% CI 
0.53-4.07, p=0.01) and 2.54 (95% CI 0.42-4.65, p = 0.02) points respectively11.  
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In an analysis planned before the ACTIVE Dialysis study was completed, we aimed to investigate 
whether randomisation to extended haemodialysis hours improved self-reported sleep parameters 
and to examine the factors that predicted sleep quality in the ACTIVE Dialysis trial population.  
Methods 
 
Study Design 
The ACTIVE Dialysis trial randomised 200 participants from 40 sites across four countries to 
extended or standard hours haemodialysis between August 2009 and July 2013. It is the largest 
completed, randomised controlled trial investigating the impact of extended weekly haemodialysis 
hours. The design, baseline characteristics12 and primary results11 of the ACTIVE Dialysis trial 
have been previously reported. In brief, this international, multicentre, open-label, blinded 
endpoint-assessment trial randomised participants from both in-centre and home-based 
haemodialysis programs in Australia, Canada, China and New Zealand to receive either extended 
(≥24 hours) or standard (≤18 hours) haemodialysis over a minimum of three sessions per week for 
12 months.  The location and timing of dialysis (home or institution, nocturnal or daytime) was not 
specified and left to the discretion of the patient and treating physician. Eligibility criteria included 
age >18 years, life expectancy >6 months, not planned to receive a renal transplant within twelve 
months and not currently treated with extended hours haemodialysis. Consenting participants were 
randomized in a 1:1 ratio via a central, web-based interface using a minimisation algorithm and 
stratified according to geographical region (Australia/New Zealand vs China/Canada), dialysis 
setting (institution vs home), and dialysis duration at study entry (≤6 months vs >6 months). 
Participants and physicians were not blinded to study allocation; however endpoints were assessed 
in a blinded fashion. Participants were followed for 12 months unless they died, withdrew consent 
or were transferred to a setting that could not offer both therapies. Participants unable or unwilling 
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to adhere to randomized treatment continued to participate in planned study assessments to allow 
intention-to-treat analyses. 
Measures 
The primary outcome of the current analysis was the average intervention effect on the overall sleep 
quality score. Participants completed a number of questionnaires at baseline and every three months 
during follow up via a telephone interview conducted by study personnel blinded to the randomised 
allocation. The interview questionnaires included the Kidney Disease Quality of Life Short Form 
Questionnaire (KDQOL-SF 1.3) which incorporates the items from the SF-36 and 43 questions 
relating to kidney disease13. Four of these relate to sleep; the first determines the overall sleep 
quality score by asking participants to rate this on a scale with 0 representing “very bad” and 10 
“very good”. In addition, three subsidiary questions ask how often over the past four weeks did they 
1) “Awaken during the night and have trouble falling asleep again?” 2) “Get the amount of sleep 
you need?” and 3) “Have trouble staying awake during the day?” These answers are rated on a six 
point Likert scale with responses ranging from “none of the time” to “all of the time”. The answers 
to all four items are then scaled, producing the KDQOL sleep subscale ranging from 0-100 with 
higher scores indicating better sleep13. The KDQOL sleep subscale has been shown to have good 
internal consistency, reliability and validity14, 15 and has been correlated with other measures of 
health related quality of life5.  
Primary and Secondary Outcome 
For these analyses, we selected the overall sleep quality score as our primary outcome given its 
correlation with mortality in previous studies2, 5. We also report the KDQOL sleep subscale which 
has a demonstrated strong correlation with dedicated sleep-quality questionnaires such as the 
Pittsburgh Sleep Quality Index (PSQI)15. 
Statistical analysis 
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Data is presented as means and standard deviation (SD) for normally distributed variables and 
median and interquartile ranges (IQR) when non-normally distributed. Comparison of means and 
medians were performed using the Student’s t-test or the Mann-Whitney U test where appropriate. 
All analyses were conducted on an intention-to-treat basis assessing the average intervention effect 
from each follow up visit for the difference between the two intervention groups. All participants 
were included in the analysis regardless of whether dialysis was nocturnal or diurnal. Average 
intervention effect was estimated from a mixed linear regression model incorporating time point 
and baseline score. No imputation was performed for the missing data points. Generalised 
estimating equation modelling (incorporating variables specified a priori for hypothesised impact 
on sleep scores: total dialysis hours per week, age, gender, time on dialysis (≤6 months or >6 
months), dialysis location, smoking status, number of co-morbidities, body mass index and baseline 
EQ5D score) was used to predict self-reported overall sleep quality and, separately, to define the 
relationship with quality of life measures. The association of baseline overall sleep quality score 
with risk of hospitalisation during the intervention period was also investigated using logistic 
regression. Statistical analyses were performed using SAS Enterprise Guide 5.1 (SAS Institute 
Inc.). 
Ethics 
The ACTIVE Dialysis clinical trial was approved by the Human Research Ethics Committee of 
Northern Sydney Central Coast Health, NSW, Australia (HREC/09/HARBR/26) and each centre 
obtained additional approval in accordance with local requirements. The trial is registered at 
clinicaltrials.gov (NCT00649298). All patients provided written, informed consent.  
 
Results 
Baseline results 
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Baseline characteristics are shown in Table 1. The median weekly dialysis hours in the extended 
group was 24 hours (IQR 24,24) compared with 12 hours (IQR 12,16) in the standard group. 
Nocturnal dialysis comprised a portion or the entirety of weekly dialysis hours for 14% of follow up 
visits in the extended hours group and 5% in the standard hours group (Table S1).  KDQOL sleep 
domain responses were available for a minimum of 82% of participants at each time point. Mean 
baseline overall sleep quality score was 6.1 (95%CI 5.8-6.5) and the mean sleep subscale score was 
64.1 (95%CI 61.2-67.0). There were no significant baseline differences in mean scores on overall 
sleep quality score or any of the three subsidiary questions (Table S2).  
Effect of Randomisation  
There was no significant interaction between time and intervention effect on either measure of sleep 
quality (results not shown). Both the primary outcome of overall sleep quality score and the 
secondary outcome of sleep subscale score increased from baseline in the extended hours group 
while remaining unchanged in the standard hours group. However, these differences did not reach 
statistical significance and were not apparent at the final time point. Over the duration of the trial, 
no significant average intervention effect was apparent in overall sleep quality (0.44, 95%CI -0.01-
0.89, p=0.053) (Figure 1a) or sleep subscale (3.58, 95% CI -0.02-7.18, p=0.051) (Figure 1b, Table 
S3). The results were similar for the three subsidiary questions (Table S2). 
Factors impacting on sleep quality 
Regression analysis demonstrated female gender and current smoking status to be predictors of poor 
overall sleep quality score. A positive association with quality of life as measured by EQ5D (Table 
2) was also seen. When considered individually, EQ5D, PCS and MCS all correlated with overall 
sleep quality score (Table 3). When adjusted for age, gender and treatment allocation, nocturnal 
dialysis had no impact on overall sleep quality, although the number of participants practising 
nocturnal dialysis was small (Table S4). Post-hoc observational analyses demonstrated a significant 
positive relationship between total weekly dialysis hours and overall sleep quality that remained 
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after adjustment for baseline overall sleep quality, age, gender and smoking status (p=0.04)(Table 
S5). This result should be interpreted with caution given the exploratory nature of the analyses. 
Associations of outcomes with baseline sleep quality  
Hospitalisation was inversely associated with overall sleep quality (odds ratio 0.85; 95%CI 0.73-
0.98; p=0.03) in univariate analysis although the association disappeared after adjustment for 
confounders (OR 0.89, 95%CI 0.76-1.04; p=0.14) (Table S6).  
 
Discussion 
  
Extended dialysis did not have a significant effect on sleep quality in the ACTIVE Dialysis trial; 
either for the overall sleep quality score, the sleep subscale or its individual component questions. 
The average treatment effect of extended hours dialysis approached statistical significance for both 
overall sleep quality score (p=0.054) and sleep subscale score (p=0.051) and it is possible that the 
lack of a clear difference was due to inadequate power, as this trial was not powered specifically to 
assess sleep. Nonetheless, the effect would need to be much larger than that observed in this trial to 
normalise sleep satisfaction.  
Our population reported better sleep quality than the general haemodialysis population2 where the 
mean overall sleep quality score and sleep subscale score has been estimated at 5.5– 5.82, 5 and 
58.716 respectively. This may be explained by selection bias where participation in a randomized 
trial of extended hours dialysis is likely to have led to a substantial underrepresentation of patients 
with a higher co-morbidity burden. Additionally, our trial cohort was relatively younger than the 
general haemodialysis population12, 17. However, the sleep quality of the present cohort remains 
poor with the mean baseline sleep subscale score in our cohort of 64.1 falling substantially below 
the threshold of 76 identified (with reference to the well-accepted Pittsburgh Sleep Quality Index) 
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as indicative of poor quality sleep in dialysis patients15. The results further highlight the problem of 
poor sleep in dialysis patients. 
There is no accepted agreement on what difference in sleep subscale score or overall sleep quality 
score represents a clinically meaningful difference (as distinct from a statistically significant 
difference).  There are multiple ways to address this general issue, including distributional 
approaches based on comparing the size of the between group difference to the variation within the 
population as a whole or attempts to anchor differences in score with accepted clinically meaningful 
events. A simple and commonly applied distributional approach calculates the ratio of the effect 
size to the population standard deviation (a value known as Cohen’s d) and suggests that effect 
sizes be thought of as <0.2 (small), 0.2-0.5 (moderate) and >0.5 (large)18. In the case of the present 
study, this results in values of 0.18 and 0.17 (for overall sleep quality and sleep subscale scores, 
respectively) suggesting that any effect present is, at best, small. Moreover, the average intervention 
effect we observed on the sleep subscale (3.6) was only a fraction of that required to lift the average 
sleep subscale score of 64.1 out of the ‘poor quality’ range, raising further uncertainty as to the 
clinical significance of the effect seen.   
Previous studies have produced conflicting results on factors associated with poor sleep in dialysis 
populations.  Multiple factors have been shown to affect sleep quality. Female gender and current 
smoking are inconsistently associated with lower quality sleep2, 5, 19. Nicotine is known to cause 
poor sleep latency, sleep fragmentation and reduced sleep efficiency20, and as data on comorbid 
respiratory disease was not available in the ACTIVE study, residual confounding from smoking-
related respiratory disorders cannot be excluded in the present analysis. The influence of gender on 
sleep is undoubtedly complex. Sleep disturbance is a more common manifestation of depression 
amongst women than men and depression is common in patients with ESKD1, 21. It is possible that 
the observed gender imbalance in sleep quality in the present study at least partly reflects differing 
symptoms of depression. Mental health issues such as depression and anxiety can themselves 
contribute to poor sleep quality as can the use of associated medications such as hypnotics. While 
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we were not able to directly assess the effect of depression or anxiety, we were able to demonstrate 
a positive association with quality of life as measured by the EQ-5D instrument. We were not able 
to test the impact of hypnotics. An association between age or BMI and sleep quality is not 
consistently found in previous studies2, 5 and was also not evident in participants of the ACTIVE 
study. We did find an association between poor sleep and poor quality of life, including both lower 
PCS and MCS, similar to multiple previous studies6, 15.  
Earlier studies have not shown correlation of sleep quality scores with urea clearance (Kt/V)6 nor 
significant improvement in sleep quality with increasing Kt/V or with the use of a high-flux 
membrane22. However, observational studies have reported a positive association between more 
frequent and/or extended weekly hours dialysis (a state of improved molecular clearance) and sleep 
quality4, 8. These positive associations contrast with the negative results from three previous 
randomised controlled trials reporting on sleep outcomes with frequent or extended dialysis and 
sleep. Neither the FHN Daily Trial of increased session frequency nor the FHN Nocturnal or 
Alberta trials of frequent nocturnal haemodialysis found an impact on sleep quality9, 10. The present 
trial differs from these trials in that the intervention was achieved mainly by lengthening the 
duration of dialysis sessions while maintaining a thrice-weekly dialysis frequency and in that there 
were few participants performing nocturnal dialysis. The results of ACTIVE would be consistent 
with the hypothesis that sleep quality can be improved through a dialysis prescription that increases 
clearances beyond that of routine dialysis but avoids the physiological and cognitive demands of 
nocturnal dialysis. However, a cautious interpretation is warranted for a number of reasons. We did 
not observe an interaction between nocturnal dialysis and the effect of treatment on sleep quality, 
although the ability to detect a difference is likely to have been limited by the small sample size of 
those dialysing at night. Also, the absolute difference in sleep quality between the two groups in the 
present study was not large and, as in the FHN trials10, appears to narrow at the final visit for 
reasons that were not apparent (despite treatment adherence remaining stable through the duration 
of the trial11). Thus, the hypothesis that extended hours dialysis improves sleep quality remains 
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speculative until further evidence distinguishing the impact of daytime versus night-time dialysis on 
sleep emerges. 
The pathophysiology of sleep disorders in dialysis patients is complex and multifactorial. 
Objectively measured reductions in sleep quality are evident in patients with chronic kidney disease 
and more severe disturbances are seen in dialysis patients23. Mean polysomnography parameters are 
markedly abnormal in dialysis patient cohorts, even after excluding patients with chronic conditions 
or medications that may contribute to poor sleep quality. Parameters including total sleep time, 
sleep latency, REM latency, brief arousal index, periodic leg movement index and sleep efficiency 
are markedly worse in dialysis patients compared to healthy controls23.  
Concomitant pathology such as uraemic pruritus, RLS and peripheral neuropathy may all directly 
disturb the sleep of patients with advanced renal disease5, 6. Furthermore, comorbid obstructive 
sleep apnoea and congestive heart failure are more common and both are associated with poor sleep 
quality. These pathologies interact adversely to worsen sleep quality. Hypervolaemia causing 
pharyngeal oedema is a postulated exacerbator of obstructive sleep apnoea24 while correction of 
fluid overload by dialysis has been shown to reduce apnoea-hypopnoea index in haemodialysis 
patients with OSA24. Chronic metabolic acidosis and the rapid shifts in cerebrospinal pH following 
dialysis are thought to affect central respiratory drive and contribute to the increased prevalence of 
central sleep apnoea in dialysis patients25. Hypocapnia due to respiratory compensation for 
metabolic acidosis interacts with co-existing fluid overload to destabilize respiratory control25. 
These mechanisms have been postulated to explain the findings of observational studies showing 
improvements in apnoea-hypopnoea index in haemodialysis patients changed from standard dialysis 
to frequent nocturnal dialysis4 and the association between lower serum bicarbonate and poorer 
sleep quality26.  However, the relationship between serum bicarbonate and sleep may be complex as 
metabolic acidosis may actually improve central sleep apnoea but worsen obstructive sleep apnoea 
by inducing stronger diaphragmatic and thoracic muscle action in the setting of poor pharyngeal 
tone27. More recently, dysregulation of circadian rhythm has emerged as a potential important 
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contributor to poor sleep in patients with end-stage kidney disease.  Patients on haemodialysis 
demonstrate suppression of the normal diurnal variation in melatonin and cortisol levels and marked 
alterations in peripheral expression of circadian clock gene mRNA. It is hypothesised that impaired 
clearance of centrally derived mediators of circadian rhythm leads to the loss of effective circadian 
signalling to peripheral tissues28. The complex interaction between poor sleep, multiple co-
morbidities and overall health may explain the correlation between adverse changes in biochemical 
parameters including albumin, haemoglobin and phosphate and sleep quality6, 23, 29.  
The optimal treatment for sleep disorders in haemodialysis patients is not known. Multiple 
interventions have shown promise in small, short-term studies, including melatonin, cognitive 
behavioural therapy, exercise training, correction of anaemia and acupressure30, 31. Additionally, 
treatment of sleep-disturbing conditions such as RLS, uremic pruritus and peripheral neuropathy 
has been associated with improvement in sleep quality32-34.  
The strengths of this study are our use of repeated measurements using a reliable, validated measure 
of sleep quality over the 12-month study period. The ACTIVE trial enrolled a diverse population, 
increasing the generalisability of the results. However, the relatively young mean age of participants 
confirms that (as is usual for extended hours or home dialysis studies) older and frailer patients 
were not well represented meaning caution is required in generalizing the results to those patient 
populations. Similarly, most of our participants performed dialysis during daylight hours and so our 
results may not be generalizable to nocturnal dialysis. The main limitation of the study is its 
relatively small size. Also, we did not use a dedicated sleep assessment tool such as the PSQI15, 
Medical Outcomes Study Sleep Problems Index10, a sleep diary, nor a direct measure of sleep 
metrics such as polysomnography. However, the KDQOL sleep subscale has been shown to 
correlate with the PSQI15. The advantages of the KDQOL sleep section in studies where sleep 
assessment is not the primary objective are the relative simplicity of use and its incorporation in a 
larger questionnaire, capturing other valuable quality of life data15.   We were also unable to adjust 
for other potential confounders such as anxiety and depression or the use of hypnotic medications.  
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Conclusion 
 
Dialysis patients suffer high rates of sleep problems and improving sleep quality is an important 
priority. Extended hours haemodialysis did not significantly improve sleep quality in this 
randomised controlled trial. Sleep quality is positively correlated with quality of life in 
haemodialysis patients and is poorer in women and current smokers. 
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Table 1: Baseline patient characteristics  
Characteristics 
Standard 
(N = 100) 
Extended 
(N = 100) 
Total 
(N = 200) 
Mean age at randomisation (SD) 51.6 (11.50) 52.1 (12.72) 51.8 (12.10) 
Male (%) 70 (70.0%) 69 (69.0%) 139 (69.5%) 
Primary cause of renal disease    
   Diabetic Nephropathy 34 (34.0%) 27 (27.0%) 61 (30.5%) 
   Hypertension/Vascular Nephrosclerosis 11 (11.0%) 11 (11.0%) 22 (11.0%) 
   Glomerulonephritis 34 (34.0%) 41 (41.0%) 75 (37.5%) 
   Reflux Nephrology 5 (5.0%) 3 (3.0%) 8 (4.0%) 
   Polycystic Kidney Disease 7 (7.0%) 5 (5.0%) 12 (6.0%) 
   Other or unknown 9 (9.0%) 13 (13.0%) 22 (11.0%) 
Smoking status    
   Never smoked 56 (56.0%) 60 (60.0%) 116 (58.0%) 
   Past cigarette smoker 23 (23.0%) 20 (20.0%) 43 (21.5%) 
   Current cigarette smoker 21 (21.0%) 20 (20.0%) 41 (20.5%) 
Diabetes Mellitus 39 (39.0%) 34 (34.0%) 73 (36.5%) 
Congestive Cardiac Failure 13 (13.0%) 19 (19.0%) 32 (16.0%) 
Country    
   Australia 28 (28.0%) 30 (30.0%) 58 (29.0%) 
   Canada 6 (6.0%) 5 (5.0%) 11 (5.5%) 
   China 62 (62.0%) 62 (62.0%) 124 (62.0%) 
   New Zealand 4 (4.0%) 3 (3.0%) 7 (3.5%) 
Ethnicity    
   Asian 60 (60.0%) 58 (58.0%) 118 (59.0%) 
   Caucasian 23 (23.0%) 22 (22.0%) 45 (22.5%) 
   Other 17 (17.0%) 20 (20.0%) 38 (18.5%) 
Number of dialysis sessions per week    
   2 1 (1.0%) 1 (1.0%) 2 (1.0%) 
   3 82 (82.0%) 86 (86.0%) 168 (84.0%) 
   4 or more 17 (17.0%) 13 (13.0%) 30 (15.0%) 
Mean total number of hours on dialysis per 
week (SD) 
14.1 (2.8) 13.6 (2.6) 13.9 (2.7) 
Duration on dialysis at enrolment, median 
(IQR) in years 
2.63 (0.97, 
6.74) 
2.43 (0.67, 
5.04) 
2.48 (0.72, 6.00)
Intended Dialysis site for study treatment    
   Home 25 (25%) 26 (26%) 51 (25.5%) 
   Institution 75 (75.0%) 74 (74.0%) 149 (74.5%) 
Nocturnal dialysis (all or part of weekly 
dialysis performed at night) 
6 (6.0%) 4 (4%) 10 (5.0%) 
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Characteristics 
Standard 
(N = 100) 
Extended 
(N = 100) 
Total 
(N = 200) 
Body Mass Index, median (IQR) in kg/m2 24.9 (22.5, 
29.3) 
24.3 (21.2, 
27.9) 
24.5 (21.9, 29.0)
EQ5D, mean (SD) 0.76 (0.25) 0.79 (0.23) 0.78 (0.24) 
Sleep quality scores from KDQOL-SF, mean 
(SD) 
   
   Overall Sleep Quality  6.3 (2.31) 5.9 (2.67) 6.1 (2.50) 
   Sleep Subscale 65.0 (20.71) 63.2 (20.83) 64.1 (20.74) 
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Table 2: Factors predicting overall sleep quality score in ACTIVE Dialysis cohort  
Result of GEE model; dependent variable sleep quality score, also adjusted for study visit. Negative 
estimates indicate worse sleep score. 
Factor Estimate (95% CI) p-value 
Total dialysis hour per week 0.02 (-0.02, 0.06) 0.36 
Age -0.02 (-0.04, 0.00) 0.10 
Gender (ref=Male)   
   Female -0.65 (-1.24, -0.06) 0.03 
Time on dialysis (ref=over 6 
months) 
  
   <=6 months 0.41 (-0.44, 1.26) 0.34 
Dialysis location 
(ref=Institution) 
  
   At home 0.00 (-0.76, 0.77) 0.99 
Smoking status (ref=Never 
smoked) 
  
   Past smoker -0.47 (-1.15, 0.21) 0.18 
   Current smoker -0.70 (-1.37, -0.02) 0.04 
Number of comorbidities (0-6) -0.25 (-0.55, 0.06) 0.11 
BMI -0.01 (-0.07, 0.04) 0.60 
EQ5D 2.97 (1.68, 4.25) <0.001 
History of diabetes  0.64 (-0.14, 1.42) 0.11 
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Table 3: Association of overall sleep quality score with quality of life measures  
GEE model; dependent variable sleep quality score; independent variables QOL measure, time and 
treatment allocation. Note the estimated magnitudes of the relationship between QOL and overall 
sleep quality score cannot be compared between EQ5D and PCS/MCS due to the different scales 
used for each instrument. 
QOL measure 
Estimate (95% 
CI) p-value  
EQ5D 1.76 (1.03, 2.48) <0.01 
SF36 MCS 0.05 (0.04, 0.07) <0.01 
SF36 PCS 0.05 (0.03, 0.07) <0.01 
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